Imvaxincis A Clinical Stage Biotechnology Company Based In Philadelphiapennsylvaniafounded In 2015The Company Aims To Improve Treatment Options For Patients With Glioblastoma And Other Cancers That Have Unmet Medical Needsimvax Develops Personalizedwhole Tumor Derived Immunotherapies Using Its Goldspirea C Platform Technologywhich Captures A Tumor S Full Antigen Signature To Enhance Immune Responses Against Tumor Cells The Company S Lead Programigv 001Is Currently Undergoing A Phase 2B Trial For Newly Diagnosed Glioblastomaimvax Has Reported A Revenue Of $10 1 Million And Has Raised A Total Of $209 45 Million In Fundingwith A Recent Financing Round Of $35 Millionthe Team Includes Experienced Leaders Such As Ceo John Pfurey And Co Founder Drdavid Wandrewswho Oversee The Company S Clinical Development And Strategic Planning
